静脉注射免疫球蛋白治疗在重度寻常型天疱疮中的作用。
The role of IVIg treatment in severe pemphigus vulgaris.
作者信息
Baum S, Scope A, Barzilai A, Azizi E, Trau H
机构信息
Department of Dermatology, Sheba Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Israel.
出版信息
J Eur Acad Dermatol Venereol. 2006 May;20(5):548-52. doi: 10.1111/j.1468-3083.2006.01540.x.
BACKGROUND
High-dose intravenous immunoglobulin (IVIg) has become a part of the treatment armentarium in pemphigus vulgaris (PV). Some consider IVIg as an adjuvant steroid sparing agent in PV, while others as disease modifying that can be used as monotherapy.
METHODS
We report our experience with a series of 12 PV patients with severe disease treated with IVIg as an adjuvant therapy.
RESULTS
Ten of 12 patients (83%) showed response to six cycles of IVIg, six (50%) having complete remission and four (33%) having a partial response. This response rate is concordant with previous reports. The therapy was well tolerated. In all 12 patients, treatment with IVIg allowed a gradual reduction of prednisone dose compared with baseline levels.
CONCLUSION
IVIg treatment was beneficial as a steroid sparing agent in our series of patients with severe PV.
背景
大剂量静脉注射免疫球蛋白（IVIg）已成为寻常型天疱疮（PV）治疗手段的一部分。一些人认为IVIg是PV中一种辅助性的类固醇节约剂，而另一些人则认为它是一种可用于单一疗法的疾病修饰剂。
方法
我们报告了一系列12例重症PV患者接受IVIg辅助治疗的经验。
结果
12例患者中有10例（83%）对六个周期的IVIg治疗有反应，6例（50%）完全缓解，4例（33%）部分缓解。该反应率与先前报道一致。该疗法耐受性良好。在所有12例患者中，与基线水平相比，IVIg治疗使泼尼松剂量逐渐减少。
结论
在我们这组重症PV患者中，IVIg治疗作为一种类固醇节约剂是有益的。
Zotero 插件